Dr. Cooke is a consultant to NovaDigm Therapeutics where he has been since joining as Chief Executive Officer in 2009. He has broad leadership experience in both emerging and large multinational companies in the fields of vaccines and immunotherapeutics. Prior to NovaDigm, Dr. Cooke was COO of AVANT Immunotherapeutics (acquired by CellDex Therapeutics) and CEO of Mojave Therapeutics (acquired by Agenus). He joined Merck when it launched a dedicated vaccine business unit in 1991 and was a key contributor to establishing a global sales and marketing organization. Dr. Cooke has a bachelor’s degree from Saint Joseph’s University, and a Ph.D. in bio-organic chemistry and an M.B.A. from Columbia University. Dr. Cooke is currently the biotechnology industry representative to the National Vaccine Advisory Committee of the Department of Health and Human Services and is Senior Vice President of Commercial Business at Ology Bioservices.
1:45 PM–2:45 PM Jun 6, 2018